144: Filer Information

Filer CIK

0001676170

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE

TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

MAZE THERAPEUTICS, INC.

SEC File Number

001-42490

Address of Issuer

171 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO
CALIFORNIA
94080

Phone

650-850-5070

Name of Person for Whose Account the Securities are To Be Sold

Jason V Coloma

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common Stock

Morgan Stanley Smith Barney LLC
Executive Financial Services
1 New York Plaza, 8th Floor
New York � NY � 10004

23497

623400

55549168

09/02/2026

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common Stock

09/01/2026

Restricted Stock Unit Vesting

Issuer

23497

09/01/2026

Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Coloma Family Trust DTD 06/27/2016
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

06/22/2026

1953

50780.93

The Coloma 2021 Irrevocable Trust DTD 09/20/2021
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

06/22/2026

2040

53040.00

Coloma Family Trust DTD 06/27/2016
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

06/23/2026

23865

621673.70

The Coloma 2021 Irrevocable Trust DTD 09/20/2021
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

07/01/2026

2593

77726.21

Coloma Family Trust DTD 06/27/2016
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

07/01/2026

31908

956526.67

The Coloma 2021 Irrevocable Trust DTD 09/20/2021
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

08/03/2026

2593

69329.14

Coloma Family Trust DTD 06/27/2016
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

08/03/2026

31908

852985.88

The Coloma 2021 Irrevocable Trust DTD 09/20/2021
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

09/01/2026

2593

68214.05

Coloma Family Trust DTD 06/27/2016
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco � CA � 94080

Common Stock

09/01/2026

31908

838784.74

144: Remarks and Signature

Remarks

The reported sale was mandated by the Issuer and includes an amount necessary to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units granted pursuant to an equity incentive award.

Date of Notice

09/02/2026

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jason V. Coloma

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)